Czech National Bank’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$44.6M Buy
353,398
+15,504
+5% +$2.04M 0.24% 75
2026
Q1
$47.1M Buy
337,894
+10,745
+3% +$1.5M 0.31% 59
2025
Q4
$40.2M Buy
327,149
+12,009
+4% +$1.46M 0.26% 75
2025
Q3
$35M Buy
315,140
+11,080
+4% +$1.26M 0.24% 82
2025
Q2
$33.7M Buy
304,060
+17,748
+6% +$1.89M 0.26% 72
2025
Q1
$32.1M Buy
286,312
+16,096
+6% +$1.66M 0.29% 66
2024
Q4
$25M Buy
270,216
+16,598
+7% +$1.49M 0.23% 82
2024
Q3
$21.3M Buy
253,618
+16,209
+7% +$1.24M 0.21% 95
2024
Q2
$16.3M Buy
237,409
+18,174
+8% +$1.21M 0.19% 107
2024
Q1
$16.1M Buy
219,235
+962
+0.4% +$74K 0.21% 103
2023
Q4
$17.7M Buy
218,273
+480
+0.2% +$37.4K 0.25% 86
2023
Q3
$16.3M Buy
217,793
+70,145
+48% +$5.4M 0.26% 81
2023
Q2
$11.4M Buy
147,648
+745
+0.5% +$59.4K 0.26% 84
2023
Q1
$12.2M Buy
146,903
+101
+0.1% +$8.37K 0.3% 75
2022
Q4
$12.6M Buy
146,802
+1,143
+0.8% +$90.5K 0.34% 71
2022
Q3
$8.99M Buy
+145,659
New +$9.19M 0.26% 81

Other funds holding GILD

Czech National Bank's GILD Position: Q2 2026 in Review

Czech National Bank increased its Gilead Sciences (GILD) stake by 4.6% in Q2 2026, buying an estimated $2.04M and bringing the position to 353,398 shares worth $44.6M. The position accounts for 0.24% of the portfolio, ranked #75.

Czech National Bank first reported a position in GILD in Q3 2022 and has held it in 16 quarters since. The position peaked at $47.1M in Q1 2026. 836 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Czech National Bank held 353,398 shares of Gilead Sciences worth $44.6M as of Q2 2026.
  • Czech National Bank bought 15,504 Gilead Sciences shares in Q2 2026, an estimated $2.04M.
  • Gilead Sciences made up 0.24% of Czech National Bank's portfolio in Q2 2026, its #75 holding.
  • Czech National Bank first reported a position in Gilead Sciences in Q3 2022 and has held it in 16 quarters since.
  • Czech National Bank's Gilead Sciences position peaked at $47.1M in Q1 2026.
  • 836 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Czech National Bank's 13F filing for Q2 2026, filed 8 Jul 2026.